

Richard J Santen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5609430/richard-j-santen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

8,802
citations

56
h-index

92
g-index

137
ext. papers

9,553
ext. citations

6.8
avg. IF

5.81
L-index

#	Paper	IF	Citations
128	WITHDRAWN - Administrative Duplicate Publication: Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. <i>Post Reproductive Health</i> , 2021 , 27, NP2-NP10	1.2	
127	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	10
126	Estrogen Replacement in Turner Syndrome 2020 , 93-122		
125	Systemic estradiol levels with low-dose vaginal estrogens. <i>Menopause</i> , 2020 , 27, 361-370	2.5	19
124	Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. <i>Menopause</i> , 2020 , 27, 614-624	2.5	4
123	Approach to Managing a Postmenopausal Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	1
122	Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019 , 7, 2324709619841414	1.2	
121	Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells. <i>Breast Cancer: Basic and Clinical Research</i> , 2019 , 13, 1178223419844198	2.2	3
120	History of Estrogen: Its Purification, Structure, Synthesis, Biologic Actions, and Clinical Implications. <i>Endocrinology</i> , 2019 , 160, 605-625	4.8	14
119	Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study. <i>Climacteric</i> , 2019 , 22, 3-12	3.1	10
118	Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome. <i>Clinical Endocrinology</i> , 2019 , 90, 155-161	3.4	9
117	Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1790-1803	5.6	41
116	Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen. <i>International Journal of Cancer</i> , 2018 , 143, 1259-1268	7.5	8
115	Glucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3630-3639	5.6	12
114	Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017 , 170, 61-64	5.1	7
113	Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. <i>Menopause</i> , 2017 , 24, 589-595	2.5	8
112	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3647-3661	5.6	62

111	Career Advancement: Meeting the Challenges Confronting the Next Generation of Endocrinologists and Endocrine Researchers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4512-4520	5.6	4
110	Progression of Metabolic Syndrome Severity During the Menopausal Transition. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	69
109	Atypical hyperplasia of the breast--risk assessment and management options. <i>New England Journal of Medicine</i> , 2015 , 372, 78-89	59.2	207
108	Adenosine monophosphate activated protein kinase (AMPK), a mediator of estradiol-induced apoptosis in long-term estrogen deprived breast cancer cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 821-30	5.4	16
107	Estrogens and Their Genotoxic Metabolites Are Increased in Obese Prepubertal Girls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2322-8	5.6	30
106	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3975-4011	5.6	434
105	Estrogen metabolites and breast cancer. <i>Steroids</i> , 2015 , 99, 61-6	2.8	99
104	Celebrating 75 years of oestradiol. <i>Journal of Molecular Endocrinology</i> , 2015 , 55, T1-20	4.5	52
103	Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 733-47	5.6	21
102	Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. <i>Breast Cancer Research</i> , 2014 , 16, 212	8.3	8
101	Competency in menopause management: whither goest the internist?. <i>Journal of Women's Health</i> , 2014 , 23, 281-5	3	17
100	Menopausal hormone therapy and breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 142, 52-61	5.1	31
99	Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. <i>Cancer Prevention Research</i> , 2014 , 7, 211-7	3.2	150
98	Hormone Responsive Cancers 2014 , 651-698.e14		
97	Occult breast tumor reservoir: biological properties and clinical significance. <i>Hormones and Cancer</i> , 2013 , 4, 195-207	5	18
96	Effects of menopausal hormonal therapy on occult breast tumors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013 , 137, 150-6	5.1	22
95	Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. <i>Steroids</i> , 2013 , 78, 161-70	2.8	146
94	Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro. <i>Endocrinology</i> , 2013 , 154, 656-65	4.8	33

93	Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. <i>Journal of Experimental Therapeutics and Oncology</i> , 2013 , 10, 169-79	0.8	0
92	3. Mechanisms Relating Estrogens to Breast Cancer. <i>Translational Endocrinology & Metabolism</i> , 2012 , 75-93		7
91	Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. <i>Endocrinology</i> , 2012 , 153, 5706-15	4.8	37
90	Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1038-48	4	38
89	Aromatase immunoreactivity is increased in mammographically dense regions of the breast. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 243-52	4.4	45
88	Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 109-17	4.4	35
87	Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 779-89	4.4	12
86	Pharmacokinetics and pharmacodynamics of oral and transdermal ¹⁷ β-estradiol in girls with Turner syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3502-10	5.6	61
85	Estrogen stimulation of cell migration involves multiple signaling pathway interactions. <i>Endocrinology</i> , 2010 , 151, 5146-56	4.8	49
84	Postmenopausal hormone therapy: an Endocrine Society scientific statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, s1-s66	5.6	429
83	Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010 , 118, 219-30	5.1	70
82	TMS, a chemically modified herbal derivative of resveratrol, induces cell death by targeting Bax. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 265-77	4.4	15
81	Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. <i>International Journal of Cancer</i> , 2010 , 127, 1748-57	7.5	77
80	Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. <i>Endocrinology</i> , 2009 , 150, 2036-45	4.8	26
79	Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1155, 132-40	6.5	67
78	Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. <i>Steroids</i> , 2009 , 74, 586-94	2.8	71
77	Assessing individual risk for breast cancer: role of oestrogens and androgens. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S10	8.3	6
76	Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. <i>Steroids</i> , 2008 , 73, 1318-21	2.8	42

75	Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 343-51	4.4	8
74	Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 630, 19-34	3.6	47
73	Standardization of steroid hormone assays: why, how, and when?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1713-9	4	158
72	Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. <i>Endocrinology</i> , 2007 , 148, 4091-101	4.8	113
71	Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. <i>Cancer Research</i> , 2007 , 67, 1352-60	10.1	159
70	Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. <i>Cancer Research</i> , 2007 , 67, 5717-26	10.1	28
69	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007 , 14, 169-87	5.7	141
68	Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. <i>Steroids</i> , 2007 , 72, 666-71	2.8	117
67	Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 105, 106-14	5.1	15
66	Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 102-10	5.1	76
65	The oestrogen paradox: a hypothesis. <i>Endokrynologia Polska</i> , 2007 , 58, 222-7	1.1	2
64	Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13 Suppl 1, S3-13	5.7	59
63	Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. <i>Anti-Cancer Drugs</i> , 2006 , 17, 33-40	2.4	8
62	Benign breast disorders. <i>New England Journal of Medicine</i> , 2005 , 353, 275-85	59.2	202
61	Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 155-65	5.1	69
60	Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. <i>International Journal of Cancer</i> , 2005 , 117, 746-54	7.5	27
59	Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1407-13	5.6	35
58	Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. <i>Molecular Endocrinology</i> , 2005 , 19, 175-83		48

57	Long-term exposure to tamoxifen induces hypersensitivity to estradiol. <i>Clinical Cancer Research</i> , 2004 , 10, 1530-4	12.9	47
56	The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 2076-81	11.5	290
55	The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. <i>Prostate</i> , 2004 , 58, 325-34	4.2	17
54	Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 337S-45S	12.9	56
53	Inhibition of aromatase: insights from recent studies. <i>Steroids</i> , 2003 , 68, 559-67	2.8	67
52	Risk of breast cancer with progestins: critical assessment of current data. <i>Steroids</i> , 2003 , 68, 953-64	2.8	45
51	Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003 , 86, 265-74	5.1	73
50	Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. <i>Molecular Endocrinology</i> , 2002 , 16, 116-27		338
49	To block estrogen synthesis or action: that is the question. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3007-12	5.6	48
48	Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. <i>Endocrinology</i> , 2002 , 143, 3221-9	4.8	79
47	Treatment of urogenital atrophy with low-dose estradiol: preliminary results. <i>Menopause</i> , 2002 , 9, 179-87.5		88
46	Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 294, 926-33	3.4	86
45	The role of mitogen-activated protein (MAP) kinase in breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002 , 80, 239-56	5.1	312
44	Aromatase inhibitors in breast cancer 2002 , 75-106		3
43	Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. <i>Cancer</i> , 2001 , 92, 2095-101	6.4	33
42	Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 79, 115-25	5.1	79
41	Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2000 , 62, 167-75	4.4	79
40	Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. <i>Endocrinology</i> , 2000 , 141, 396-405	4.8	145

39	Regulated CYP19 aromatase transcription in breast stromal fibroblasts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 837-46	5.6	25
38	Relative versus attributable risk of breast cancer from estrogen replacement therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1875-81	5.6	16
37	Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2104-9	5.6	118
36	Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. <i>Endocrinology</i> , 1998 , 139, 4164-74	4.8	136
35	The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer. <i>Obstetrical and Gynecological Survey</i> , 1998 , 53, S1-83	2.4	17
34	Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 200-8	5.6	69
33	Meeting summary: Workshop conference on endocrine therapy of advanced prostate cancer, airline house, November 3-4, 1996. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1997 , 3, 31-8	2.8	2
32	Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. <i>Cancer</i> , 1995 , 75, 2132-8	6.4	87
31	The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993 , 44, 687-91	5.1	68
30	The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993 , 44, 683-5	5.1	11
29	An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. <i>New England Journal of Medicine</i> , 1991 , 324, 317-22	59.2	102
28	Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 99-106	5.6	40
27	Estrone sulfate stimulates growth of nitrosomethylurea-induced breast carcinoma in vivo in the rat. <i>International Journal of Cancer</i> , 1990 , 46, 73-8	7.5	26
26	A phase I trial of CGS 16949A. A new aromatase inhibitor. <i>Cancer</i> , 1990 , 65, 1279-85	6.4	60
25	Endocrine treatment of breast cancer in women. <i>Endocrine Reviews</i> , 1990 , 11, 221-65	27.2	330
24	Novel methods of oestrogen deprivation for treatment of breast diseases. <i>Proceedings of the Royal Society of Edinburgh Section B Biological Sciences</i> , 1989 , 95, 255-269		2
23	Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. <i>Prostate</i> , 1987 , 11, 229-42	4.2	292
22	Aromatase activity in primary and metastatic human breast cancer. <i>Cancer</i> , 1987 , 59, 779-82	6.4	117

21	Treatment of breast cancer with gonadotropin-releasing hormone. <i>Endocrine Reviews</i> , 1986 , 7, 89-94	27.2	78
20	Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. <i>Annals of the New York Academy of Sciences</i> , 1986 , 464, 126-37	6.5	93
19	Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. <i>Prostate</i> , 1985 , 7, 41-51	4.2	109
18	Ablative procedures in patients with metastatic breast carcinoma. <i>Cancer</i> , 1984 , 53, 762-5	6.4	10
17	Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. <i>Cancer</i> , 1984 , 53, 1447-50	6.4	79
16	Animal model of isolated gonadotropin deficiency. I. Hormonal responses to LHRH immunoneutralization. <i>Journal of Andrology</i> , 1983 , 4, 233-9		15
15	Animal model of isolated gonadotropin deficiency. II. Morphologic responses to LHRH immunoneutralization. <i>Journal of Andrology</i> , 1983 , 4, 240-7		12
14	Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma. <i>Steroids</i> , 1982 , 39, 497-507	2.8	69
13	Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. <i>Annals of Internal Medicine</i> , 1982 , 96, 94-101	8	144
12	Recovery of hypothalamic-pituitary-adrenal function after long term suppression by aminoglutethimide and hydrocortisone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981 , 53, 879-82 ^{5.6}		5
11	A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. <i>New England Journal of Medicine</i> , 1981 , 305, 545-51	59.2	178
10	The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. <i>Cancer</i> , 1980 , 46, 1066-74	6.4	42
9	Resistance of the ovary to blockade of aromatization with aminoglutethimide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980 , 51, 473-7	5.6	107
8	Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 704-11	2.9	65
7	Prolonged negative feedback suppression after estradiol administration: proposed mechanism of eugonadal secondary amenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1978 , 47, 1220-9	5.6	18
6	Adrenal suppression with aminoglutethimide. I. Differential effects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1977 , 45, 469-79	5.6	61
5	Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1977 , 45, 739-46	5.6	37
4	Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. <i>Cancer</i> , 1977 , 39, 2948-58 ^{6.4}		73

3	Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. <i>Journal of Urology</i> , 1976 , 115, 170-4	2.5	55
2	Effect of aminophylline on the secretion of insulin, glucagon, luteinizing hormone and growth hormone in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1970 , 31, 153-61	5.6	26
1	Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo		34